shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

    PAR-21-137

    National Institutes of Health

    Opening date 2 Mar 2021, 12:00AM

    Closing date 15 Feb 2024, 12:00AM

    Funding Opportunity Number: PAR-21-137

    Opportunity Category: Discretionary

    CFDA Number(s): 93.242 -- Mental Health Research Grants

    Cost Sharing or Matching Requirement: No

    Posted Date: Mar 02, 2021 12:00:00 AM EST

    Closing Date: Feb 15, 2024 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification),State governments,Small businesses,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),For profit organizations other than small businesses,Native American tribal organizations (other than Federally recognized tribal governments),Private institutions of higher education,County governments,Special district governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,City or township governments,Independent school districts,Public housing authorities/Indian housing authorities

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description:

    This is a reissue of RFA-MH-18-702: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

    Grantor Contact Information: NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept